Bleeding and clotting cases following Covid-19 vaccination in India are minuscule but definitive and in line with the expected number of such diagnoses, a report submitted by the national committee on the Adverse Effects Following Immunisation (AEFI) on Monday said.
The government decided to conduct an in-depth analysis of adverse events in India in light of global concerns, the health ministry said. Some countries on March 11 raised an alert on post-vaccination embolic and thrombotic events, particularly with AstraZeneca-Oxford vaccine — Covishield in India, the ministry said.
The reporting rate of these events in India is around 0.61 per million doses, lower than the 4 cases per million reported by UK’s regulator Medical and Health Regulatory Authority. Germany has reported 10 events per million doses.
The ministry is issuing advisories to health care workers and vaccine beneficiaries to be aware of suspected thromboembolic symptoms occurring within 20 days after receiving any Covid vaccine, particularly Covishield, and report preferably in the health facility where the dose was given.
The AEFI data in India showed that there is a very miniscule but definitive risk of thromboembolic events. Such events refer to the formation of a clot in a blood vessel that might also break loose and be carried by the bloodstream to plug another vessel. There were no potential thromboembolic events reported following administration of Covaxin vaccine.
The committee has completed an in-depth case review of 498 serious and severe events, of which 26 have been reported to be potential thromboembolic events — following the administration of Covishield.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU